Abdel PN

Language: Spanish
References: 16
Page: 105-113
PDF size: 287.45 Kb.

ABSTRACT

Introduction: Neurocysticercosis is still a common problem in countries living the epidemiological transition towards development.
Case report: Herein is presented the case of a 66-year-old Mexican male, with long-standing diabetes, under hemodialysis, with persistent headache associated with nausea and fatigue, without response to conventional analgesics, cranial tomography exhibited findings suggestive of cysticerci, which is confirmed by immunological tests. The patient was treated with praziquantel and albendazol for 2 weeks, showing complete response and remission of symptoms.
Conclusion: Neurocysticercosis should be suspected in endemic countries, especially in immunocompromised individuals.

REFERENCES

1. Botero D. Teniasis-cisticercosis. En: Goldsmith R, Heyneman D, editores Parasitología y Medicina Tropical. México DF: Manual Moderno; 1995: 632-46.

2. Evans C A W, García H H, Gilman R H. Larval cestode infections: Cysticercosis. En: Strickland GT, Ed. Hunter’s Tropical Medicine and Emerging Infectious Diseases. Philadelphia: W.B.Saunders; 1999: 862-5.

3. Bouteille B. Epidemiology of cysticercosis and neurocysticercosis. Med Sante Trop. 2014; 24(4):367- 374.

4. García H, González A, Martínez S, Gilman R. Teniasis / cisticercosis por taenia solium un serio problema de Salud Pública en el Perú. Oficina General de Epidemiología, Lima 2001: 7-19.

5. Flisser A. Risk factors and control measures for taeniosis/cysticercosis. En: Craig P, Pawlowski Z, editores. Cestode Zoonoses: Echinococcosis and Cysticercosis, An Emergent and Global Problem. Amsterdam: IOS Press, NATO Science Series Vol. 341, 2002; 335-342.

6. Sorvillo F, Wilkins P, Shafir S, Eberhard M. Public health implications of cysticercosis acquired in the United States. Emerg Infect Dis 2011;17:1-6

7. Secretaría de Salud. Modificación a la Norma Oficial Mexicana NOM-021-SSA2-1994, para la prevención y control del complejo teniosis/cisticercosis en el primer nivel de atención médica. México: Diario Oficial de la Federación; 2004. Disponible en: http://www.salud.gob.mx/unidades/ cdi/nom/ m021ssa294.html

8. Kimura-Hayama ET, Higuera JA, Corona-Cedillo R, Chávez Macías L, Perochena A, Quiroz-Rojas LY, et al. Neurocysticercosis: radiologicpathologic correlation. Radiographics. 2010;30:1705-19

9. Del Brutto OH. Neurocisticercosis: actualización en diagnóstico y tratamiento. Neurología. 2005; 20:412-8.

10. Náquira C. Taenia solium: biological cycle and characteristics. En: García HH, Martinez SM. Taenia solium. Taeniasis/Cysticercosis. 2da. edición. Lima: Ed. Universo; 1999: 7-14. 4.

11. Pawlowski Z, Allan J, Sarti E. Control of Taenia solium taeniasis / cysticercosis: from research towards implementation. Int J Parasitol 2005; 35: 1221-32

12. Vidal S. Comunicación de un caso de cisticercosis subcutánea. Rev Chilena Infectol 2013; 30 (3): 323-325.

13. Del Brutto OH, Rajshekhar V, White JR AC, Tsang VC, Nash TE, Takayanagui OM, et al. Proposed diagnostic criteria for neurocysticercosis. Neurology. 2001; 57:177-83

14. Sarria-Estrada S, Frascheri-Verzelli L, Siurana-Montilva S, Auger-Acosta C, Rovira-Cañellas A. Neurocisticercosis. Hallazgos radiológicos. Radiología 2013;55(2):130-141.

15. Del Brutto OH. Neurocysticercosis. The Neurohospitalist 2014;4(4): 205-212

16. Garcia HH, Gonzales I, Lescano AG, Bustos JA, Zimic M, Escalante D, et al (Cysticercosis Working Group in Peru). Efficacy of combined antiparasitic therapy with praziquantel and albendazole for neurocysticercosis: a double-blind, randomised controlled trial. Lancet Infect Dis. 2014;14(8):687- 95.